Skip to main content
SpringerLink
Log in
Book cover

Prostatic Artery Embolization pp 21–42Cite as

Medical Management of Benign Prostatic Hyperplasia

  • Chapter
  • First Online:

Abstract

The goal of medical management for benign prostatic hyperplasia (BPH) is to improve lower urinary tract symptoms (LUTS) of affected patients. Therapy is generally focused on mitigating the dynamic or static components of BPH pathophysiology. Alpha-adrenergic receptor blockers (alpha-blockers) are the most common first-line medication for BPH and function by inhibiting dynamic prostatic smooth muscle contraction to prevent bladder outlet obstruction. The medications in this class are equally effective and well tolerated, but medication side effects of hypotension, dizziness, and retrograde ejaculation determine specific medication selection for treatment. Androgen manipulation via 5 alpha-reductase inhibitors alleviates static components of LUTS by decreasing prostate size. This medication class can potentiate sexual side effects but has been shown to be extremely effective in conjunction with alpha-blockers. Phosphodiesterase inhibitors have demonstrated efficacy in treating men with BPH and coexisting erectile dysfunction, but their mechanism of improving LUTS is unclear. Anticholinergic and beta-3-agonist medications are indicated for patients with overactive bladder symptoms in the setting of BPH due to their ability to reduce detrusor spasms and increase bladder relaxation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attribbuted to benign prostatic hyperplasia: AUA guideline. Linthicum Heights: American Urology Association; 2018.

    Google Scholar 

  2. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.

    Article  PubMed  Google Scholar 

  3. Miller DC, Saigal CS, Litwin MS. The demographic burden of urologic diseases in America. Urol Clin North Am. 2009;36(1):11–27.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975;47(2):193–202.

    Article  CAS  PubMed  Google Scholar 

  5. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent areadensity of prostate smooth muscle. Prostate. 1992;21(4):297–307.

    Article  CAS  PubMed  Google Scholar 

  6. Gup DI, Shapiro E, Baumann M, Lepor H. Contractile properties of human prostate adenomas and the development of intravesical obstruction. Prostate. 1989;15(2):105–14.

    Article  CAS  PubMed  Google Scholar 

  7. James S, Chapple C, Phillips M, Greengrass P, Davey M, Turner-Warwick R, et al. Autoradiographic analysis of the alpha-adrenoreceptos and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol. 1989;142(2 Pt 1):438–44.

    Article  CAS  PubMed  Google Scholar 

  8. Forray C, Bard J, Wetzel J. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45:703–8.

    CAS  PubMed  Google Scholar 

  9. Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, et al. Localization of endothelin receptors in the human prostate. J Urol. 1994;151(3):763–6.

    Article  CAS  PubMed  Google Scholar 

  10. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50(7):551–4.

    Article  CAS  PubMed  Google Scholar 

  11. Ferrie B, Paterson P. Phenoxybenzamine in prostatic hypertrophy a double blind study. Br J Urol. 1987;59(1):63–5.

    Article  CAS  PubMed  Google Scholar 

  12. Ruutu M, Hansson E, Juusela H, Permi J, Rusk J, Sotarauta M, et al. Efficacy and side effects of prazosin as a symptomatic treatment of benign prostatic obstruction. Scand J Urol Nephrol. 1991;25(1):15–9.

    Article  CAS  PubMed  Google Scholar 

  13. Jardin A, Bensadoun H, Delauche-Cavallier M, Attatli P. Alfuzosin for benign prostatic hypertrophy. Lancet. 1991;338(8772):947.

    Article  CAS  PubMed  Google Scholar 

  14. Alabaster V, Davey M. The alpha 1-adrenoceptor antagonist profile of doxazosin; preclinical pharmacology. Br J Clin Pharmacol. 1986;21(Suppl 1):9S–17S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Elliot H, Meredith P, Reid J. Pharmacokinetic overview of doxazosin. Am J Cardiol. 1987;59(14):78G–81G.

    Article  Google Scholar 

  16. Sonders R. Pharmacokinetics of terazosin. Am J Med. 1986;80(5B):20–4.

    Article  CAS  PubMed  Google Scholar 

  17. Guay D. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004;2(1):14–23.

    Article  CAS  PubMed  Google Scholar 

  18. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia United States 93-01 Study Group. J Urol. 1998;160:1701–6.

    Article  CAS  PubMed  Google Scholar 

  19. Ding H, Du W, Hou Z, Wang H, Wang Z. Silodosin is effective for treatment of LUTS in men with BPH: a systemic review. Asian J Androl. 2013;15(1):121–8.

    Article  CAS  PubMed  Google Scholar 

  20. Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld K, et al. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol. 2010;70(1):88–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lepor H, Hill L. Sildosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010;30(12):1303–12.

    Article  CAS  PubMed  Google Scholar 

  22. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, et al. The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia HYCAT Investigator Group. Urology. 1996;47(2):159–68.

    Article  CAS  PubMed  Google Scholar 

  23. Terazosin Abbot Laboratories. Hytrin (terazosin hydrochloride tablet) [package insert]. US Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf. Revised 07/2009. Accessed July 1, 2019.

  24. Cr C, Carter P, Christmas TJ, Kriby RS, Bryan J, Milroy EJ, et al. A three month double blind study of doxazosinas treatment for benign prostatic obstruction. Br J Urol. 1994;74(1):50–6.

    Article  Google Scholar 

  25. Fawzy A, Braun K, Lewis G, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol. 1995;154(1):105–9.

    Article  CAS  PubMed  Google Scholar 

  26. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double blind, placebo-controlled, dose response multicenter study. J Urol. 1995;154(1):110–5.

    Article  CAS  PubMed  Google Scholar 

  27. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bouedillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol. 1994;74(5):579–84.

    Article  CAS  PubMed  Google Scholar 

  28. Buzelin J, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol. 1997;31(2):190–8.

    Article  CAS  PubMed  Google Scholar 

  29. Van Kerrebroeck P, Jardin A, Laval K, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37(3):306–13.

    Article  PubMed  Google Scholar 

  30. Roerborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blinded, placebo-controlled studies. BJU Int. 2003;92(3):257–61.

    Article  CAS  Google Scholar 

  31. Yamada S, Tanaka C, Kimua R, Kawabe K. Alpha 1-adrenoreceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci. 1994;54(24):1845–54.

    Article  CAS  PubMed  Google Scholar 

  32. Wilt T, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction; a systematic review of efficacy and adverse effects. J Urol. 2002;167(1):177–83.

    Article  CAS  PubMed  Google Scholar 

  33. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Uses of an α1-Blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol. 1990;144(4):908–11.

    Article  CAS  PubMed  Google Scholar 

  34. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective α1c-adrenoreceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76(3):325–36.

    Article  CAS  PubMed  Google Scholar 

  35. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51(6):892–900.

    Article  CAS  PubMed  Google Scholar 

  36. Abrams P, Speakman M, Stott M, Arkell D, Pocock R. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective α1A-adrenoreceptor antagonist, in patients with benign prostatic obstruction. BJU Int. 1997;80(4):587–96.

    Article  CAS  Google Scholar 

  37. Chapple C, Wyndaele J, Nording J, Boeminghaus F, Ypma A, Abrams P. Tamsulosin, the first prostate-selective 1A-adrenoreceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155–67.

    CAS  PubMed  Google Scholar 

  38. Ding H, Du W, Hou ZZ, Wang HZ, Wang ZP. Sildosin is effective for treatment of LUTS in men with BPH: a systematic review. Asian J Androl. 2013;15(1):121–8.

    Article  CAS  PubMed  Google Scholar 

  39. Kawabe K, Yoshida M, Homma Y. Silodosin. A new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.

    Article  CAS  PubMed  Google Scholar 

  40. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.

    Article  CAS  PubMed  Google Scholar 

  41. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active controlled clinical trial performed in Europe. Eur Urol. 2012;(5):38–42, 44–5.

    Google Scholar 

  42. Lepor H. Long term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology. 1995;45(3):406–13.

    Article  CAS  PubMed  Google Scholar 

  43. Van Dijk M, de la Rosette J, Michel M. Effects of alpha(1)-adrenoreceptor antagonists on male sexual function. Drugs. 2006;66(3):287–301.

    Article  PubMed  Google Scholar 

  44. Buzelin J, Fonteyne E, Kontturi M, Witjes WP, Khan A. Comparison of tamsulosin with alfuzosin in treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol. 1997;80(4):597–695.

    Article  CAS  PubMed  Google Scholar 

  45. Nordling J. Efficacy and safety of two doses (10mg and 15mg) of alfuzosin or tamsulosin (0.4mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005;95(7):1006–12.

    Article  CAS  PubMed  Google Scholar 

  46. Shakir S, Pearce G, Mann RD. Finesteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription event monitoring data. BJU Int. 2001;87:789–96.

    Article  CAS  PubMed  Google Scholar 

  47. Brookes S, Donovan J, Peters T, Abrams P, Neal D. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomized control trial. BMJ. 2002;324(7345):1059–61.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Hellstrom WJ, Smith W, Sikka SC. Effects of alpha blockers on ejaculatory function in normal subjects. J Urol. 2006;173(4 Pt 1):1529–33.

    Article  CAS  Google Scholar 

  49. Chang D, Campbell J. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664–73.

    Article  PubMed  Google Scholar 

  50. Wilson J. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980;68(5):745–56.

    Article  CAS  PubMed  Google Scholar 

  51. Siiteri P, Wilson J. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest. 1970;49(9):1737–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Moore R, Gazyk J, Quebbeman J, Wilson J. Concentration of dihydrotestosterone and 3a-androstanediol in naturally occurring and androgen induced prostatic hyperplasia in the dog. J Clin Invest. 1979;64(4):1003–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. McConnell J. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate. 1990;17(S3):49–59.

    Article  Google Scholar 

  54. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5a-reductase in humans. Prostate. 1989;14(1):45–53.

    Article  CAS  PubMed  Google Scholar 

  55. Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol. 1998;11:393–422.

    Article  CAS  PubMed  Google Scholar 

  56. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnel JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91.

    Article  CAS  PubMed  Google Scholar 

  57. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety study Group. N Engl J Med. 1998;228(9):557–63.

    Article  Google Scholar 

  58. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.

    CAS  PubMed  Google Scholar 

  59. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.

    Article  CAS  PubMed  Google Scholar 

  60. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41.

    Article  PubMed  Google Scholar 

  61. Mocellini IA, Gardiner R, Marshall V, Johnson W, Bartsch G, Schmidbauer CP, et al. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 1993;22(4):291–9.

    Article  Google Scholar 

  62. Marberger M. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology. 1998;51(5):677–86.

    Article  CAS  PubMed  Google Scholar 

  63. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43(3):284–92; discussion 292-4.

    Article  CAS  PubMed  Google Scholar 

  64. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrhorn C. Efficacy and safety of long-term treatment with dual 5-alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–94; discussion 495

    Article  CAS  PubMed  Google Scholar 

  65. Guess H, Heyse J, Gormley G. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22(1):31–7.

    Article  CAS  PubMed  Google Scholar 

  66. Wein A, Kavoussi L, Partin A, Peters C. Chapter 104, evaluation and nonsurgical management of benign prostatic hyperplasia. In: Campbell-Walsh urology. 11th ed. Philadelphia: Elsevier; 2016.

    Google Scholar 

  67. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.

    Article  CAS  PubMed  Google Scholar 

  68. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of Dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.

    Article  CAS  PubMed  Google Scholar 

  69. Burnett A. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M–31M.

    Article  CAS  PubMed  Google Scholar 

  70. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “aging male” symptoms? Results of the “Cologne male survey”. Eur Urol. 2003;44(5):588–94.

    Article  CAS  PubMed  Google Scholar 

  71. Blanker MH, Bohnen AM, Groeneveld FP, Bersen RM, Prins A, Thomas S, et al. Correlates for erectile dysfunction in older men: a community-based study. J Am Geriatr Soc. 2001;49(4):436–42.

    Article  CAS  PubMed  Google Scholar 

  72. Moreira ED, Lbo CF, Diament A, Nicolsi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology. 2003;61(2):431–6.

    Article  PubMed  Google Scholar 

  73. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, et al. The association between lower urinary tract symptoms and erectile dysfuntion in four centers: the UrEpik study. BJU Int. 2003;92(7):719–25.

    Article  CAS  PubMed  Google Scholar 

  74. Brookes S, Link C, Donovan J, McKinlay J. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area Community Health Survey. J Urol. 2008;179(1):250–5.

    Article  PubMed  Google Scholar 

  75. Sairam K, Kulinskaya E, McNicholas T, Boustead G, Hanbury D. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836–9.

    Article  CAS  PubMed  Google Scholar 

  76. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7.

    Article  CAS  PubMed  Google Scholar 

  77. Roehrboen C, McVary K, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia; a dose finding study. J Urol. 2008;180(4):1228–34.

    Article  CAS  Google Scholar 

  78. Porst H, Oekle M, Goldfischer ER, Cox D, Watts S, Dey D, et al. Efficacy and safety of tadalifil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analysis of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82(3):667–73.

    Article  PubMed  Google Scholar 

  79. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2012;61(5):994–1003.

    CAS  Google Scholar 

  80. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Slidenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trail. J Urol. 2007;177(3):1071–7.

    Article  CAS  PubMed  Google Scholar 

  81. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in helathy subjects. Br J Clin Pharmacol. 2006;61(3):280–8.

    Article  CAS  PubMed  Google Scholar 

  82. Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int. 2010;106:674–80.

    Article  CAS  PubMed  Google Scholar 

  83. Thomas A, Abrams P. Lower urinary tract symptoms benign prostatic obstruction, and the overactive bladder. BJU Int. 2000;85(3):57–68.

    Article  PubMed  Google Scholar 

  84. Abrams P. Detrusor instability and bladder outlet obstruction. Neurourol Urodyn. 1985;4(4):317–28.

    Article  Google Scholar 

  85. Speakerman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, Gosing JA. Bladder outflow obstruction—a cause of denervation super sensitivity. J Urol. 1987;136(6):1461–6.

    Article  Google Scholar 

  86. Greenland J, Brading A. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol. 2001;165:245.

    Article  CAS  PubMed  Google Scholar 

  87. Elbadawi A, Yalla S, Resnick N. Structural basis for geriatric voiding dysfunction. III. Detrusor overactivity. J Urol. 1993;150(5 Pt 2):1668–80.

    Article  CAS  PubMed  Google Scholar 

  88. Abramov Y, Sand P. Oxybutynon for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother. 2004;5(11):2351–9.

    Article  CAS  PubMed  Google Scholar 

  89. Elterman D, Kaplan S, Barkin J. Tolterodine for treatment of urge incontinence. Expert Opin Pharmacother. 2013;14(14):1987–91.

    Article  CAS  PubMed  Google Scholar 

  90. Blake-James B, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systemic review and meta-analysis. BJU Int. 2007;99(1):85–96.

    Article  CAS  PubMed  Google Scholar 

  91. Martin-Merino E, Garcia Rodriguez L, Masso Gonzales E, Roehrborn C. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol. 2009;182(4):1442–8.

    Article  PubMed  Google Scholar 

  92. Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in management of overactive bladder. Ther Adv Urol. 2012;288:1367–73.

    Google Scholar 

  93. Suarez O, Osborn D, Kaufman M, Reynolds WS, Dmochowski R. Curr Urol Rep. 2013;14(6):580–4.

    Article  PubMed  Google Scholar 

  94. Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, et al. Absorption, metabolism and excretion of (14)mirabegron (YM178), a potent and selective β(3)-adrenoreceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815–24.

    Article  CAS  PubMed  Google Scholar 

  95. Chapple C, Cardozo L, Victor W, Nitti V, Siddiqui E, Michel M. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33:17–30.

    Article  CAS  PubMed  Google Scholar 

  96. Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, et al. Proarrythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double blind placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706.

    Article  CAS  PubMed  Google Scholar 

  97. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milson I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.

    Article  CAS  PubMed  Google Scholar 

  98. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.

    Article  CAS  PubMed  Google Scholar 

  99. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double blind, parallel-group, placebo-controlled, multicenter study to assess the efficacy and safety of β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.

    Article  PubMed  Google Scholar 

  100. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.

    Article  CAS  PubMed  Google Scholar 

  101. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gromley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med. 1996;335(8):533–9.

    Article  CAS  PubMed  Google Scholar 

  102. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–26.

    Article  PubMed  Google Scholar 

  103. Debruyne FMJ, Jardin A, Colloi D, Resel L, Wities WPJ, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, Finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol. 1998;34(3):169–75.

    Article  CAS  PubMed  Google Scholar 

  104. McConnell JD, Roehrborn C, Bautista O, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long term effect of doxazosin, finasteride and combination theraopy on clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

    Article  CAS  PubMed  Google Scholar 

  105. Kaplan SA, Roehrborn CG, Rovner ES, Carisson M, Bavendam T, Gaun Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28.

    Article  CAS  PubMed  Google Scholar 

  106. Kaplan SA, Walmsely K, Te A. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273–6.

    Article  PubMed  Google Scholar 

  107. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. BJU Int. 2004;94:817–20.

    Article  CAS  PubMed  Google Scholar 

  108. Kaplan S, Roehrborn C, Gong J, Sun F, Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109(12):1831–40.

    Article  CAS  PubMed  Google Scholar 

  109. Van Kerrebroeck P, Haab F, Angulo JC, Vik V, Katona F, Garcia-Hernandez A, et al. Efficacy and safety of solifenacin pluc tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol. 2013;64(3):398–407.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of North Carolina School of Medicine, Chapel Hill, NC, USA

    Victor C. Showalter

  2. Department of Urology, University of North Carolina Hospitals, Chapel Hill, NC, USA

    Mathew C. Raynor

Authors
  1. Victor C. Showalter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathew C. Raynor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor C. Showalter .

Editor information

Editors and Affiliations

  1. Department of Radiology, University of North Carolina, School of Medicine, Chapel Hill, NC, USA

    Ari J. Isaacson

  2. Vascular and Interventional Radiology, Vascular Institute of Virginia, Woodbridge, VA, USA

    Sandeep Bagla

  3. Department of Urology, University of North Carolina Hospitals, Chapel Hill, NC, USA

    Mathew C. Raynor

  4. Division of Vascular and Interventional Radiology, Department of Radiology, University of North Carolina, School of Medicine, Chapel Hill, NC, USA

    Hyeon Yu

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Showalter, V.C., Raynor, M.C. (2020). Medical Management of Benign Prostatic Hyperplasia. In: Isaacson, A., Bagla, S., Raynor, M., Yu, H. (eds) Prostatic Artery Embolization. Springer, Cham. https://doi.org/10.1007/978-3-030-23471-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-23471-3_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-23470-6

  • Online ISBN: 978-3-030-23471-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation